Schizophrenia Drugs Market by Drug Class, Geography & Forecast to 2027

1
Drug Class First Generation Drugs, Second
Generation Drugs, and Third Generation Drugs
Route of Administration Oral and
InjectableForecast From 2019 - 2027
Schizophrenia Drugs Market
2
Table of Content
Sr. No. Content
Chapter 1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary Global Schizophrenia Drugs Market
Chapter 4 Market Overview
Chapter 5 Key Insights
Chapter 6 Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class 
Chapter 7 Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration 
Chapter 8 Global Schizophrenia Drugs Market Analysis and Forecast, by Region
Chapter 9 Europe Schizophrenia Drugs Market Analysis and Forecast
Chapter 10 Asia Pacific Schizophrenia Drugs Market Analysis and Forecast
Chapter 11 Latin America Schizophrenia Drugs Market Analysis and Forecast
Chapter 12 Middle East Africa Schizophrenia Drugs Market Analysis and Forecast
Chapter 13 Competition Landscape
3
Schizophrenia Drugs Market Snapshot

• Several doctors and healthcare providers are
  adopting the methods of polypharmacology to
  develop new drugs for mental disorders.
• Rise in the prevalence of schizophrenia,
  approvals for additional indications, and launch
  of new schizophrenia drugs are driving the
  schizophrenia drugs market.
• Schizophrenia drugs market has been categorized
  into first generation drugs, second generation
  drugs, and third generation drugs.

4
(No Transcript)
5
Reports Highlights

• Global schizophrenia drugs market is projected to
  reach to the value of US 15.7 bn by the end of
  2027. The schizophrenia drugs market is projected
  to witness a 4 CAGR to achieve this value.
• Key Players
• Janssen Global Services, LLC (Johnson
  Johnson), ALLERGAN, Pfizer Inc., and Otsuka
  Holdings Co., Ltd.

Request Sample
6
(No Transcript)